The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.
BACKGROUND AND AIMS: Heart failure with preserved ejection fraction (HFpEF) with obesity remains a therapeutic challenge with limited options. They may have an adjunctive role, although larger, longer-term dedicated outcome trials are needed.
BACKGROUND AND AIMS: Heart failure with preserved ejection fraction (HFpEF) with obesity remains a therapeutic challenge with limited options. They may have an adjunctive role, although larger, longer-term dedicated outcome trials are needed.
What the study was
- Study design
- Meta-Analysis
- Population
- Patient/participant population (size not extracted)
- Category
- Prevention
- Maturity
- Potentially Practice-Changing
- Journal
- Nutrition, metabolism, and cardiovascular diseases : NMCD
Why it surfaced
Scored 8/10 (Meta-Analysis; novelty=2, relevance=3, design_quality=2, population_or_unmet_need=1). HIGH priority.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.